← Back to Search

Imaging

Dixon MRI for Prostate Cancer

N/A

Waitlist Available

Led By Ganeshan Dhakshina Moorthy

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Biopsy proven prostate cancer patients who are scheduled to undergo prostatectomy

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial uses MRI with Dixon-based imaging to detect prostate cancer. Researchers hope to learn if this will produce better images than the standard MRI scan.

Who is the study for?

This trial is for men with biopsy-proven prostate cancer who have consented to participate, are scheduled for prostate removal surgery (prostatectomy), and a standard MRI scan. It's not open to those who've had hormone or radiation therapy affecting the pelvis or prostate, prefer other treatments over surgery, or can't have MRIs due to metal implants or pacemakers.Check my eligibility

What is being tested?

The study is testing whether a modified MRI technique using Dixon based imaging sequences can provide better images of prostate cancer compared to the usual MRI scans. The goal is to see if this new scanning method improves the detection and visualization of prostate tumors.See study design

What are the potential side effects?

Since this trial involves an investigational imaging technique rather than a drug, there are no direct side effects like you'd expect from medication. However, typical MRI-related concerns such as discomfort from lying still may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have prostate cancer confirmed by biopsy and will have surgery to remove my prostate.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Detection of at least one or more prostate lesions with Dixon sequencing

Side effects data

From 2022 Phase 3 trial • 53 Patients • NCT00033293

19%

87900-Vomiting(targeted toxicity)

15%

11400-Agitation

11600-Alanine aminotransferase increased

16800-Bladder infection

44800-Infections and infestations - Other specify

58700-Nystagmus

15000-Aspartate aminotransferase increased

88500-White blood cell decreased

15300-Ataxia

33900-Fever

25700-Diarrhea

43100-Hypokalemia

69700-Rash maculo-papular(targeted toxicity)

13200-Anemia

33300-Febrile neutropenia

57600-Nausea(targeted toxicity)

20500-Catheter related infection

58300-Neutrophil count decreased

41300-Hypercalcemia

41400-Hyperglycemia(targeted toxicity)

41600-Hyperkalemia

42600-Hypoalbuminemia

42700-Hypocalcemia

64400-Personality change

41500-Hyperhidrosis

13500-Anorexia

100%

80%

60%

40%

20%

Study treatment Arm

Arm I (Chemotherapy, Immunoglobulin Therapy)

Arm II (Chemotherapy, Observation)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (standard MRI, Dixon MRI)Experimental Treatment2 Interventions

Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Magnetic Resonance Imaging

2017

Completed Phase 3

~1180

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,964 Previous Clinical Trials

1,804,389 Total Patients Enrolled

95 Trials studying Prostate Cancer

29,675 Patients Enrolled for Prostate Cancer

National Cancer Institute (NCI)NIH

13,636 Previous Clinical Trials

40,929,484 Total Patients Enrolled

560 Trials studying Prostate Cancer

507,106 Patients Enrolled for Prostate Cancer

Ganeshan Dhakshina MoorthyPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Dixon MRI (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT05047965 — N/A

Prostate Cancer Research Study Groups: Diagnostic (standard MRI, Dixon MRI)

Prostate Cancer Clinical Trial 2023: Dixon MRI Highlights & Side Effects. Trial Name: NCT05047965 — N/A

Dixon MRI (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05047965 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to become involved in this scientific investigation?

"The clinical trial, initially posted on April 25th 2013 and last updated on September 8th 2021 is not recruiting patients. However, there are an abundance of other medical studies currently enrolling new participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

2013. "An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05047965.